Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
This article was originally published in Scrip
Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.
Register for our free email digests: